What question did this study set out to answer?

This research aims to evaluate how body mass index (BMI) influences the effectiveness of GLP-1RA therapy on bowel preparation quality.

April 15, 2026Open Access

Body Mass Index (BMI) Dependent Effect of Glucagon Like Peptide 1 Receptor Agonist (GLP-1RA) Therapy on Bowel Preparation Quality

Key Points

This research aims to evaluate how body mass index (BMI) influences the effectiveness of GLP-1RA therapy on bowel preparation quality.
Analyzed the effects of GLP-1RA therapy on bowel preparation quality among different BMI categories.
Stratified patients into normal, overweight, and severe obesity groups for comparison.
Assessed the incidence of inadequate bowel preparation across these groups.
Inadequate bowel preparation was notably higher in normal and overweight patients using GLP-1RA.
Minimal impact on bowel preparation quality was found in severely obese patients.
BMI stratification offers a framework for tailoring colonoscopy preparation.

Abstract

GLP-1RA therapy increased inadequate bowel preparation risk primarily in normal and overweight patients, with minimal effect in severe obesity. BMI stratification may inform personalized colonoscopy preparation strategies in GLP-1RA treated patients.

Body Mass Index (BMI) Dependent Effect of Glucagon Like Peptide 1 Receptor Agonist (GLP-1RA) Therapy on Bowel Preparation Quality

Key Points

Abstract

Cite This Study